Literature DB >> 16416058

[Risk adapted therapy in vascular diseases: antihypertensive treatment in peripheral arterial disease].

R Sternitzky1.   

Abstract

Arterial hypertension must also be consistently treated in patients with PAD. Current guidelines and recommendations have to be considered, although in some patients the walk performance may be affected temporary by blood pressure dropping. In PAD, ideal antihypertensives are ACE inhibitors, AT1 receptor antagonists, calcium channel blockers and also alpha receptor blockers in combination. Beta receptor blockers-indicated in coronary heart disease-do not influence pain-free walking distance (PFWD) in patients with PAD. Diuretics should only be given in low dosage and in combination with other antihypertensive drugs in order to avoid a decrease of blood flow ability with clinical events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16416058     DOI: 10.1007/s00392-005-1406-8

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  14 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

4.  Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  Michael Domanski; Gary Mitchell; Marc Pfeffer; James D Neaton; James Norman; Kenneth Svendsen; Richard Grimm; Jerome Cohen; Jeremiah Stamler
Journal:  JAMA       Date:  2002 May 22-29       Impact factor: 56.272

5.  Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level.

Authors:  Stefan Lange; Hans Joachim Trampisch; Roman Haberl; Harald Darius; David Pittrow; Alexander Schuster; Berndt von Stritzky; Gerhart Tepohl; Jens Rainer Allenberg; Curt Diehm
Journal:  Atherosclerosis       Date:  2005-02       Impact factor: 5.162

6.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.

Authors:  Judith A Whitworth
Journal:  J Hypertens       Date:  2003-11       Impact factor: 4.844

7.  Long-term epidemiologic prediction of coronary disease. The Framingham experience.

Authors:  W B Kannel; M Larson
Journal:  Cardiology       Date:  1993       Impact factor: 1.869

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  getABI: German epidemiological trial on ankle brachial index for elderly patients in family practice to dedect peripheral arterial disease, significant marker for high mortality.

Authors: 
Journal:  Vasa       Date:  2002-11       Impact factor: 1.961

10.  High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study.

Authors:  Curt Diehm; Alexander Schuster; Jens R Allenberg; Harald Darius; Roman Haberl; Stefan Lange; David Pittrow; Berndt von Stritzky; Gerhart Tepohl; Hans-Joachim Trampisch
Journal:  Atherosclerosis       Date:  2004-01       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.